Strata Critical Medical, Inc. (SRTA)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy limit 5.42 GTC at the 2026-11-05 breakout-high 5.40 / rising EMA9 5.34 pullback confluence in SRTA's post-earnings uptrend; structure stop 5.10 below the 2026-11-06 regular-session low 5.155 (1.03 ATR), targets 6.04 (2.0 ATR) and 6.51 (3.5 ATR), R/R 1.94; no breakout stop qualifies (trigger 6.15 above the settled 6.13 high gives R/R 0.59) and the shallower 5.83 / 5.58 pullbacks give R/R 0.82 / 1.22, all below the 1.5 floor.
Company overview
Strata Critical Medical, Inc. provides logistical management and specialized medical assistance to healthcare providers across the U.S., focusing on organ transportation for transplants via air and ground methods. The company, founded in 2014 and formerly known as Blade Air Mobility, Inc., is headquartered in New York, NY.
Fundamental
fairStrata shows strong revenue growth and positive cash flow, but ongoing GAAP losses and acquisition dependence persist.
Mixed but improving: revenue growth (9M-2026 +64%, +8.5% pro forma in Q3), a 21.6% gross margin, positive operating cash flow of $19.0M and a net-cash balance sheet with an undrawn $30M revolver, offset by persistent GAAP losses (trailing net loss $24.8M), acquisition-dependent growth, a 3.5% decline in the Logistics segment and negative DCF-model values; FY2026 guidance of $285-295M revenue and $33-35M Adjusted EBITDA is the key swing factor. No dividend, and no going-concern or covenant issues.
Sentiment
fairThe sentiment is constructive with an activist campaign and positive Q3 results, but lacks immediate catalysts.
The dominant catalyst is the unresolved Third Point activist campaign — a disclosed stake plus a public push for a sale (2026-10-16, announced) that the tape rewarded — layered over a Q3 2026 report the press read as mildly positive (revenue +50.3% to $74.1M, record free cash flow, $20M buyback) despite a GAAP net loss and an EPS miss versus consensus. The media sentiment delta is flat (baseline polarity ≈ +0.12 → scoring ≈ +0.10), retail is indeterminate on a Reddit access block, and the Red-Flag Screen is clean, so no cap applies; with no forward-dated catalyst inside 30 days the setup is forming rather than actionable-now.
Technical
goodThe stock is in a confirmed short-term uptrend with momentum indicators supporting further gains.
Trend frame fully bullish: last regular close 6.02 (2026-11-10) is above SMA20 4.84, SMA50 4.99, SMA200 5.09, EMA9 5.34, EMA21 5.04, WMA9 5.41, DEMA14 5.49, TEMA14 5.80 and the 5.9675 daily VWAP after the stock bottomed at 4.21 on 2026-11-02 and ran to 6.13 on 2026-11-09 (+45.6% in five sessions). Momentum confirms: MACD line 0.20 above signal 0.01 and above zero with histogram +0.19 still expanding, and ADX14 29.27 rising alongside the advance (strong UP trend, not a fading one). One clear weak signal keeps this at 4 rather than 5: RSI14 73.01 and Williams %R -5.73 are overbought and price sits ~24% above its SMA20, and the plan's R/R of 1.94 is just under the 2.0 bar. The structure stop (below the 5.155 three-session low) sits ~3.4 ATR under the current price, so a near-market entry cannot clear the R/R floor — the plan is therefore a limit into the 5.34-5.40 confluence.
You’re looking at 2026-11-11 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

